Christopher K Anderson, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5957 Fashion Point Dr Ste 103, South Ogden, UT 84403 Phone: 385-492-4930 Fax: 385-492-4449 |
Gurjeet S Grover, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5957 Fashion Point Dr, South Ogden, UT 84403 Phone: 385-492-4930 |
News Archive
Pfizer Inc. announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).
Understanding why immune cells, called T-cells, attack the body is vital in the war against autoimmune diseases like diabetes. University of Alberta researcher Troy Baldwin is a step closer to understanding why the body's T-cells sometimes attack healthy cells causing autoimmune diseases.
A study published in Journal of the American Geriatrics Society suggested that the use of certain medications in elderly populations may be associated with cognitive decline.
Alterations in our response to the taste or smell of food may be another culprit responsible for Type 2 diabetes, according to scientists at Duke University Medical Center who have identified the specific mechanism in human specimens and in mice.
ChemGenex Pharmaceuticals Limited announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid.
› Verified 9 days ago